61,784 Shares in Incyte Corporation $INCY Purchased by L2 Asset Management LLC

Posted by Francis Steltz on Aug 25th, 2026

L2 Asset Management LLC acquired a new position in Incyte Corporation (NASDAQ:INCY – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 61,784 shares of the biopharmaceutical company’s stock, valued at approximately $7,004,000.

Other large investors have also modified their holdings of the company. BlackRock Inc. bought a new position in shares of Incyte during the second quarter valued at approximately $2,044,189,000. Deutsche Bank AG bought a new stake in shares of Incyte during the 2nd quarter worth approximately $143,172,000. Norges Bank bought a new stake in shares of Incyte during the 4th quarter worth approximately $122,893,000. Caisse de depot et placement du Quebec boosted its holdings in Incyte by 264.5% during the 3rd quarter. Caisse de depot et placement du Quebec now owns 1,498,013 shares of the biopharmaceutical company’s stock valued at $127,046,000 after acquiring an additional 1,087,091 shares during the period. Finally, Marshall Wace LLP boosted its holdings in Incyte by 6,586.4% during the 4th quarter. Marshall Wace LLP now owns 1,072,491 shares of the biopharmaceutical company’s stock valued at $105,930,000 after acquiring an additional 1,056,451 shares during the period. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on INCY. Truist Financial increased their target price on Incyte from $103.00 to $105.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. UBS Group boosted their target price on shares of Incyte from $103.00 to $113.00 and gave the company a “neutral” rating in a research note on Friday, June 26th. Stifel Nicolaus set a $145.00 price target on shares of Incyte in a report on Tuesday, July 28th. Mizuho raised their price target on shares of Incyte from $121.00 to $137.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Incyte from $105.00 to $110.00 and gave the company a “neutral” rating in a report on Thursday, July 23rd. Twelve analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to data from MarketBeat, Incyte presently has a consensus rating of “Hold” and a consensus target price of $123.10.

Check Out Our Latest Stock Report on Incyte

Insider Buying and Selling at Incyte

In related news, EVP Patrick A. Mayes sold 41,899 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $119.46, for a total transaction of $5,005,254.54. Following the sale, the executive vice president owned 61,441 shares of the company’s stock, valued at $7,339,741.86. This trade represents a 40.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo J. Cagnoni sold 10,801 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total value of $1,356,173.56. Following the sale, the insider directly owned 183,200 shares in the company, valued at approximately $23,002,592. The trade was a 5.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 16.20% of the company’s stock.

Incyte Stock Up 0.1%

Shares of INCY stock opened at $127.98 on Tuesday. The firm has a market cap of $25.94 billion, a price-to-earnings ratio of 16.30, a PEG ratio of 4.05 and a beta of 0.76. The company’s 50 day moving average is $116.69 and its 200 day moving average is $104.37. Incyte Corporation has a 52-week low of $81.09 and a 52-week high of $132.60.

Incyte (NASDAQ:INCY – Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $3.09 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.94. The company had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.50 billion. Incyte had a net margin of 27.71% and a return on equity of 29.93%. Incyte’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.57 earnings per share. Analysts anticipate that Incyte Corporation will post 2.61 EPS for the current fiscal year.

Incyte Profile

(Free Report)

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.